These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 24367041

  • 21. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
    Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.
    J Hepatol; 2011 Mar; 54(3):439-48. PubMed ID: 21129805
    [Abstract] [Full Text] [Related]

  • 22. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    Sirinawasatien A, Techasirioangkun T.
    PLoS One; 2020 Mar; 15(2):e0229517. PubMed ID: 32106270
    [Abstract] [Full Text] [Related]

  • 23. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML.
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [Abstract] [Full Text] [Related]

  • 24. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.
    Holmes JA, Congiu M, Bonanzinga S, Sandhu MK, Kia YH, Bell SJ, Nguyen T, Iser DM, Visvanathan K, Sievert W, Bowden DS, Desmond PV, Thompson AJ.
    Aliment Pharmacol Ther; 2015 Aug; 42(3):296-306. PubMed ID: 26032235
    [Abstract] [Full Text] [Related]

  • 25. Treatment of hepatitis C virus genotype 3-infection.
    Pol S, Vallet-Pichard A, Corouge M.
    Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
    [Abstract] [Full Text] [Related]

  • 26. Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden.
    Lu YF, Goldstein DB, Urban TJ, Bradrick SS.
    Virology; 2015 Feb; 476():334-340. PubMed ID: 25577150
    [Abstract] [Full Text] [Related]

  • 27. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
    Boglione L, Cardellino CS, Cusato J, De Nicolò A, Cariti G, Di Perri G, D'Avolio A.
    Infect Genet Evol; 2017 Jul; 51():167-172. PubMed ID: 28315743
    [Abstract] [Full Text] [Related]

  • 28. Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C.
    Świątek-Kościelna B, Kałużna E, Strauss E, Nowak J, Bereszyńska I, Gowin E, Wysocki J, Rembowska J, Barcińska D, Mozer-Lisewska I, Januszkiewicz-Lewandowska D.
    World J Gastroenterol; 2017 Jun 07; 23(21):3815-3824. PubMed ID: 28638221
    [Abstract] [Full Text] [Related]

  • 29. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM, García-Samaniego J, García M, Madejón A, Martín-Carbonero L, Cabello A, Álvarez B, Górgolas M, Rallón N.
    J Interferon Cytokine Res; 2017 Jun 07; 37(6):278-286. PubMed ID: 28440692
    [Abstract] [Full Text] [Related]

  • 30. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.
    Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S.
    Hepatology; 2015 Mar 07; 61(3):790-801. PubMed ID: 25203718
    [Abstract] [Full Text] [Related]

  • 31. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.
    Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M, Hotta H.
    J Gastroenterol; 2012 Oct 07; 47(10):1143-51. PubMed ID: 22441534
    [Abstract] [Full Text] [Related]

  • 32. IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
    Franco S, Aparicio E, Parera M, Clotet B, Tural C, Martinez MA.
    AIDS; 2014 Jan 02; 28(1):133-6. PubMed ID: 24072198
    [Abstract] [Full Text] [Related]

  • 33. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
    Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, Cornpropst MT, Mader M, Albanis E, Jiang D, Hebner CM, Symonds WT, Berrey MM, Lalezari J.
    J Hepatol; 2013 Apr 02; 58(4):663-8. PubMed ID: 23183528
    [Abstract] [Full Text] [Related]

  • 34. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
    Aqel B, Leise M, Vargas HE, Watt KD, Keaveny AP, Zhang N, Zhang N, Pungpapong S.
    Ann Hepatol; 2018 Aug 24; 17(5):815-821. PubMed ID: 30145562
    [Abstract] [Full Text] [Related]

  • 35. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Wyles D, Pockros P, Morelli G, Younes Z, Svarovskaia E, Yang JC, Pang PS, Zhu Y, McHutchison JG, Flamm S, Lawitz E.
    Hepatology; 2015 Jun 24; 61(6):1793-7. PubMed ID: 25846014
    [Abstract] [Full Text] [Related]

  • 36. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
    Bhattacharya D, Belperio PS, Shahoumian TA, Loomis TP, Goetz MB, Mole LA, Backus LI.
    Clin Infect Dis; 2017 Jun 15; 64(12):1711-1720. PubMed ID: 28199525
    [Abstract] [Full Text] [Related]

  • 37. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratziu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, Subramanian GM, McHutchison JG, Marcellin P, Habersetzer F, Guyader D, Grangé JD, Loustaud-Ratti V, Serfaty L, Metivier S, Leroy V, Abergel A, Pol S.
    Lancet Infect Dis; 2015 Apr 15; 15(4):397-404. PubMed ID: 25773757
    [Abstract] [Full Text] [Related]

  • 38. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
    Hagan LM, Sulkowski MS, Schinazi RF.
    Hepatology; 2014 Jul 15; 60(1):37-45. PubMed ID: 24677184
    [Abstract] [Full Text] [Related]

  • 39. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.
    Fujino H, Imamura M, Nagaoki Y, Kawakami Y, Abe H, Hayes CN, Kan H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Honda Y, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hyogo H, Aikata H, Takahashi S, Miki D, Ochi H, Ohishi W, Chayama K, Hiroshima Liver Study Group.
    J Gastroenterol; 2014 Dec 15; 49(12):1548-56. PubMed ID: 24362944
    [Abstract] [Full Text] [Related]

  • 40. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
    Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A.
    Lancet Infect Dis; 2013 May 15; 13(5):401-8. PubMed ID: 23499158
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.